Point-of-care testing is the fastest-growing channel in IVD by site of testing, driven by the permanent behavioral shift toward decentralized diagnostics accelerated by COVID-19. The POC testing market is projected to grow at a CAGR exceeding 8% through 2030, outpacing central laboratory growth. Abbott's BinaxNOW and ID NOW platforms demonstrated the commercial power of near-patient diagnostics at scale. Pregnancy, influenza, strep, glucose, and COVID antigen tests have normalized home testing for hundreds of millions of consumers globally. Decentralized testing through at-home IVD kits is emerging as a transformative trend empowering individuals to monitor health conditions conveniently and privately. Emergency departments are deploying point-of-care troponin, BNP, and blood gas analyzers to accelerate clinical decisions. Microfluidics, biosensors, and smartphone-connected diagnostics are enabling test-menu expansion into previously laboratory-only applications.

This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.

Topics Covered
• POC Testing Market Size and Forecast 2025-2030 by Application and Channel
• Emergency and Critical Care POC — Troponin, BNP, Blood Gas, and Electrolytes
• Infectious Disease POC — Influenza, Strep, RSV, COVID, and Syndromic Panels
• Chronic Disease POC — Glucose, HbA1c, Lipids, and INR
• At-Home Testing — OTC Diagnostics, Direct-to-Consumer, and Prescription Home Test Markets
• POC Molecular Testing — GeneXpert, ID NOW, and Near-Patient NGS
• Microfluidics and Biosensor Technologies — Enabling the Next POC Generation
• Regulatory Framework — FDA, CLIA Waiver, and EU IVDR for POC Devices
• Competitive Landscape — Abbott, Roche, Siemens, QuidelOrtho, and Emerging Players
• Investment and Partnership Opportunities